A 3‐year follow‐up of patients with localized prostate cancer operated on with or without pre‐treatment with the GnRH‐agonist triptorelin

Publisher Website
Google Scholar
Abstract
Objective To examine the effect of pre‐operative androgen deprivation on the progression rate of malignancy in patients operated on for localized prostate cancer. Patients and methods A total of 53 patients received no hormone therapy (group 1) and a further 38 patients (group 2) received the generic releasing‐hormone agonist triptorelin during the 3 months before surgery. The patients in group 1 had T1b‐T2 tumours, whereas 12 of those in group 2 had clinical stage T3 tumours. Despite this, the surgical specimens from the patients in group 2 showed a rate of cancer invasion of the surgical margins 20% lower than those from the patients in group 1. After prostatectomy, the patients were followed for 3 years by repeated analyses of prostate‐specific antigen (PSA) in serum. Results During the follow‐up, the PSA level exceeded the upper threshold (0.6 ng/mL) in 16 % of the patients in group 1 and in 43 % of those in group 2 (P0.05), developed symptoms from skeletal metastases. Conclusion There was no evidence that pre‐operative hormone therapy slowed the progression of prostate cancer.

This publication has 0 references indexed in Scilit: